CD Biosynsis offers integrated CHO (Chinese Hamster Ovary) Cells Metabolic Pathway Optimization Services, designed to systemically enhance the productivity and stability of this premier mammalian host. CHO cells are the industry standard for producing complex biotherapeutics, including monoclonal antibodies (mAbs). Optimizing these pathways is crucial for achieving high titers and superior product quality. Our services utilize a systematic approach that combines Constraint-Based Metabolic Modeling (CBM), high-precision genome editing (CRISPR-Cas9, Base Editing, CRISPRi), and High-Throughput Screening (HTS). This integrated strategy allows for the rational identification and removal of metabolic bottlenecks, safe management of energy/redox states, and efficient reduction of toxic byproduct accumulation (lactate/ammonia). Our goal is to develop highly optimized CHO cell lines that maintain exceptional stability and performance in large-scale fed-batch bioreactors.
Get a QuoteOptimizing metabolic pathways in CHO cells is complex due to the host's pseudo-tetraploid genome and the need to balance cell growth, viability, and specific productivity (Qp). Our platform employs a systematic cycle where metabolic modeling (Design) guides the construction of engineered strains (Build). Phenotypic testing (Test) and data analysis (Learn) inform the next round of rational modifications. This systematic, data-driven methodology eliminates trial-and-error, focusing on critical pathways such as glycolysis, TCA cycle, and N-glycosylation . Key goals include minimizing the Warburg effect (lactate production) and extending the anti-apoptotic phase of the production culture.
Constraint-Based Metabolic Modeling (CBM)
Utilization of the CHO genome-scale model to predict cell fitness and productivity under varying nutrient conditions, identifying optimal targets for carbon flux redirection and enhanced ATP yield.
Metabolomics & Fluxomics
Experimental measurement of intracellular and extracellular metabolites and fluxes (via 13C tracing) to pinpoint bottlenecks in glycolysis, TCA cycle, and secretory pathway capacity.
Transcriptome & Proteome Analysis
Quantitative analysis of host cell protein (HCP) expression and mRNA levels to map cellular stress responses and the utilization of cofactors essential for high productivity.
CRISPR-Cas9 Editing
Used for stable integration of large expression cassettes (Knock-in) into safe harbor loci and multi-allelic deletion (Knockout) of pro-apoptotic or protease genes.
Base Editing (BE)
Precision single-nucleotide substitutions for fine-tuning promoter strengths, optimizing poly-A signals, or introducing subtle amino acid changes in key metabolic enzymes (e.g., LDHA).
CRISPR Interference (CRISPRi)
Tunable and reversible gene repression (knockdown) used for safely balancing flux through essential pathways (e.g., central metabolism) or testing the effect of repressing toxic pathways (e.g., ammonia cycle).
Byproduct Reduction
Targeted modification of metabolic shunts to minimize the production of inhibitory byproducts like lactate and ammonia, extending culture lifespan and boosting titer.
Glycoprofile Optimization
CRISPR-guided editing of native glycosylation enzymes (e.g., FUT8, GNAT) to achieve desired human-like N-glycan homogeneity and improve therapeutic efficacy.
Enhanced Cell Fitness
Engineering the anti-apoptosis pathways and stress response genes to improve viability and robustness under demanding industrial fed-batch conditions.
A systematic and iterative process for developing high-performance production cell lines.
1. Modeling & Target Identification
2. Precision Editing & Clone Generation
3. High-Throughput Phenotype Screening
4. Data Integration & Strain Delivery
Utilize the CHO metabolic model to identify limiting nutrient consumption, cofactor bottlenecks, and toxic byproduct pathways (lactate/ammonia).
Design a set of rational genomic modifications (e.g., KO of pro-apoptosis genes, tuning of LDHA) and regulatory tuning targets (Base Editing).
Define screening assays (e.g., titer, lactate consumption rate) based on optimization goals.
Execute multiplex genome editing (CRISPR-Cas9, Base Editing, CRISPRi) using RNP or lentiviral delivery systems.
Select for stable integration or editing events using metabolic or antibiotic selection.
Isolate single cells and generate monoclonal cell lines.
Integrate screening and assay data back into the metabolic model to validate predictions and refine design rules.
Select the final optimized clone based on titer, stability, and product quality metrics.
Delivery of the verified CHO master cell bank (MCB) and comprehensive optimization report.
Integrated DBTL Platform
Combines computational modeling, multi-tool editing (CRISPR/BE/CRISPRi), and automated HTS, ensuring a rational and highly accelerated optimization cycle for high-value bioproducts.
Byproduct & Apoptosis Control
Targeted modification of lactate/ammonia pathways and anti-apoptosis genes maximizes culture viability and extends the productive phase of the bioreactor run, boosting titer.
Glycoprofile Precision
Expertise in editing glycosylation pathways (KO/KI/BE) ensures precise control over the N-glycan profile, achieving desired homogeneity and human-like quality for therapeutic proteins.
Stable Genomic Solutions
Preference for stable integration into defined genomic safe harbor loci via HDR guarantees consistent, high-level expression and avoids the gene silencing issues of random integration.
1. What is the primary goal of CHO metabolic pathway optimization?
The primary goal is to increase the specific productivity (Qp) of the cell line and extend culture longevity while maintaining or improving product quality (e.g., glycan profile) by eliminating metabolic shunts (lactate/ammonia).
2. How does CBM (Modeling) guide the CHO optimization strategy?
CBM identifies non-intuitive metabolic bottlenecks and predicts the optimal redirection of carbon flux, allowing engineers to rationally prioritize which genes to knockout, overexpress, or repress for maximum titer gain.
3. Why is reducing lactate production so important in CHO bioprocessing?
Lactate is toxic and lowers media pH, inhibiting cell growth and productivity. Reducing lactate production frees up glucose for biomass and product synthesis and extends the viable lifespan of the cell culture.
4. Which precision tool is best for optimizing promoter strength?
Base Editing (BE) is ideal for optimizing promoter strength. It allows for single-base substitution in the promoter sequence, providing highly precise, subtle tuning of gene expression that cannot be achieved with Cas9 KO/KI.
5. How is cell viability enhanced through gene editing?
Cell viability is enhanced by knocking out pro-apoptotic genes (e.g., Bax, Bak) or repressing them (CRISPRi), which delays the onset of programmed cell death and extends the highly productive phase of the culture.
6. What is the role of Glycoprofiling in the optimization workflow?
Glycoprofiling (assay) confirms the desired N-glycan structure after genetic modification. This feedback loop is essential to ensure that metabolic optimization for titer does not negatively impact the critical quality attributes (CQAs) of the therapeutic product.
7. What input is required to start a pathway optimization project?
We require the specific CHO host cell line, details of the therapeutic product (e.g., mAb sequence), current productivity data, and the primary optimization goals (e.g., increase titer by X%, or reduce fucose by Y%).
8. What is the final output of the service?
We deliver the verified and optimized CHO master cell bank (MCB), the final metabolic model, and a detailed report covering the editing strategy, genomic verification, and fed-batch performance data (titer, viability, and CQA analysis).
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.